Academia Sinica yesterday said that its researchers have developed an antibody testing method for COVID-19 and have made progress synthesizing remdesivir, a medicine that many believe could cure the infection.
The Centers for Disease Control on Tuesday sent serum samples to Academia Sinica of three people who had contact with Taiwan’s first COVID-19 fatality, as part of an effort to determine the source of that infection.
The three had tested negative for RNA viruses, but the centers hoped to discover if they had developed antibodies.
Photo courtesy of Academia Sinica
Test results showed that only one sample had antibodies for COVID-19 and SARS, Academia Sinica Institute of Biomedical Sciences research fellow Lin Yi-ling (林宜玲) said.
The sample was obtained from a Taiwanese businessperson who was not listed as a confirmed case, because their immune system beat the virus, she said.
Little is known about COVID-19, so it is still a mystery whether a person who has recovered from it can contract it again, she added.
The method is useful in tracing the transmission chain of a certain case, Institute of Plant and Microbial Biology Director Wu Shu-hsing (吳素幸) said, but added that testing for RNA viruses tells whether a person contracts COVID-19.
Using molecular biology and genetic engineering, Wu said that she pieced together plasmids — a kind of DNA for expressing antigens — in small templates to make up longer series of plasmids for producing the antigens used to test for COVID-19, SARS and Middle East respiratory syndrome antibodies.
Ordering massive plasmid series from overseas manufacturers takes two to three weeks, Lin said, praising Wu’s team for only needing a week.
After Institute of Biological Chemistry associate research fellow Ho Meng-chiao (何孟樵) purified the nucleocapsid protein of COVID-19 for making reagents, Lin used the western blot method to place the antigens in a serum sample for testing antibody reactions, she said.
Another team led by Institute of Chemistry associate research fellow Chein Rong-jie (陳榮傑) succeeded in synthesizing 100mg of remdesivir in two weeks.
Unable to obtain the raw materials in time, they used materials on hand and molecule synthesis, referencing public-domain literature, to make the drug, which on Thursday was 97 percent as pure as the original, Chein said.
Before the centers tasked them with the mission, Academia Sinica President James Liao (廖俊智) last month formed a task force to speed up the development of antigens, antibodies, drugs and vaccines for COVID-19.
The synthesized drug cannot be used without the consent of the US pharmaceutical firm that manufactures remdesivir, Liao said.
Nonetheless, the achievement showed that Academia Sinica is capable of drug synthesis and could facilitate mass production of the drug after a technology transfer has been completed, he added.
CALL FOR SUPPORT: President William Lai called on lawmakers across party lines to ensure the livelihood of Taiwanese and that national security is protected President William Lai (賴清德) yesterday called for bipartisan support for Taiwan’s investment in self-defense capabilities at the christening and launch of two coast guard vessels at CSBC Corp, Taiwan’s (台灣國際造船) shipyard in Kaohsiung. The Taipei (台北) is the fourth and final ship of the Chiayi-class offshore patrol vessels, and the Siraya (西拉雅) is the Coast Guard Administration’s (CGA) first-ever ocean patrol vessel, the government said. The Taipei is the fourth and final ship of the Chiayi-class offshore patrol vessels with a displacement of about 4,000 tonnes, Lai said. This ship class was ordered as a result of former president Tsai Ing-wen’s (蔡英文) 2018
‘SECRETS’: While saying China would not attack during his presidency, Donald Trump declined to say how Washington would respond if Beijing were to take military action US President Donald Trump said that China would not take military action against Taiwan while he is president, as the Chinese leaders “know the consequences.” Trump made the statement during an interview on CBS’ 60 Minutes program that aired on Sunday, a few days after his meeting with Chinese President Xi Jinping (習近平) in South Korea. “He [Xi] has openly said, and his people have openly said at meetings, ‘we would never do anything while President Trump is president,’ because they know the consequences,” Trump said in the interview. However, he repeatedly declined to say exactly how Washington would respond in
WARFARE: All sectors of society should recognize, unite, and collectively resist and condemn Beijing’s cross-border suppression, MAC Minister Chiu Chui-cheng said The number of Taiwanese detained because of legal affairs by Chinese authorities has tripled this year, as Beijing intensified its intimidation and division of Taiwanese by combining lawfare and cognitive warfare, the Mainland Affairs Council (MAC) said yesterday. MAC Minister Chiu Chui-cheng (邱垂正) made the statement in response to questions by Democratic Progressive Party (DPP) Legislator Puma Shen (沈柏洋) about the government’s response to counter Chinese public opinion warfare, lawfare and psychological warfare. Shen said he is also being investigated by China for promoting “Taiwanese independence.” He was referring to a report published on Tuesday last week by China’s state-run Xinhua news agency,
‘ADDITIONAL CONDITION’: Taiwan will work with like-minded countries to protect its right to participate in next year’s meeting, the foreign ministry said The US will “continue to press China for security arrangements and protocols that safeguard all participants when attending APEC meetings in China,” a US Department of State spokesperson said yesterday, after Beijing suggested that members must adhere to its “one China principle” to participate. “The United States insists on the full and equal participation of all APEC member economies — including Taiwan — consistent with APEC’s guidelines, rules and established practice, as affirmed by China in its offer to host in 2026,” the unnamed spokesperson said in response to media queries about China putting a “one China” principle condition on Taiwan’s
RSS